TD Asset Management
DNTH icon

TD Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

TD Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22M Buy
225,334
+108,758
+93% +$9.5M 0.02% 490
2026
Q1 		$9.78M Buy
116,576
+84,826
+267% +$4.91M 0.01% 650
2025
Q4 		$1.31M Buy
31,750
+4,092
+15% +$159K ﹤0.01% 1068
2025
Q3 		$1.09M Buy
+27,658
New +$707K ﹤0.01% 1073

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

TD Asset Management's DNTH Position: Q2 2026 in Review

TD Asset Management increased its Dianthus Therapeutics (DNTH) stake by 93% in Q2 2026, buying an estimated $9.5M and bringing the position to 225,334 shares worth $22M. The position accounts for 0.02% of the portfolio, ranked #490.

TD Asset Management first reported a position in DNTH in Q3 2025 and has held it in 4 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • TD Asset Management held 225,334 shares of Dianthus Therapeutics worth $22M as of Q2 2026.
  • TD Asset Management bought 108,758 Dianthus Therapeutics shares in Q2 2026, an estimated $9.5M.
  • Dianthus Therapeutics made up 0.02% of TD Asset Management's portfolio in Q2 2026, its #490 holding.
  • TD Asset Management first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.